Strategic partnerships AtlasXomics has active and growing partnership activity, including a distribution agreement with Integrated Sciences (Jun 2026) and collaboration with EpiCypher for spatial epigenomics kits and services (Jan 2024). Leverage these alliances to co-sell, expand geographic reach, and bundle multi-omics solutions to target oncology, aging, and neuroscience customers.

Multi-omics niche The company specializes in spatial epigenomics (spatial ATAC-seq and spatial CUT&Tag) combined with histology to map chromatin and epigenetic mechanisms in tissue contexts. This multi-omics positioning creates upsell opportunities for customers adopting single-cell or bulk methods to upgrade to spatial multi-omics workflows.

Clinical and research demand With over 50 investigators helped across oncology, aging, and neuroscience, AtlasXomics demonstrates a track record in disease-focused research and translational potential. Target pharma and biotech labs pursuing mechanism discovery, biomarker validation, and therapeutic response studies within tissue microenvironments.

Growth potential Revenue range of $10M-$25M and recent funding of $5.7M indicate a scalable but still mid-stage company. This suggests opportunities for larger enterprise deals, higher-value service packages, and venture-backed collaborations with CROs for expanded multi-omics offerings.

Technology and IP leverage Commercialization of DBiT-seq for spatial ATAC-seq and upcoming CUT&Tag kits positions AtlasXomics at the forefront of spatial epigenomics tooling. Focus on enabling proteome and transcriptome readouts in the same tissue section opens cross-sell to teams using proteomics, spatial genomics, and histology platforms.